Lantz Financial LLC trimmed its stake in Johnson & Johnson (NYSE:JNJ) by 8.8% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 8,038 shares of the company’s stock after selling 771 shares during the period. Lantz Financial LLC’s holdings in Johnson & Johnson were worth $1,126,000 at the end of the most recent quarter.
A number of other large investors have also made changes to their positions in JNJ. Highwater Wealth Management LLC acquired a new position in Johnson & Johnson during the 4th quarter valued at about $215,000. DNB Asset Management AS increased its holdings in shares of Johnson & Johnson by 18.4% in the fourth quarter. DNB Asset Management AS now owns 1,564,448 shares of the company’s stock valued at $201,892,000 after purchasing an additional 243,578 shares during the period. QUANTRES ASSET MANAGEMENT Ltd increased its holdings in shares of Johnson & Johnson by 465.0% in the fourth quarter. QUANTRES ASSET MANAGEMENT Ltd now owns 33,900 shares of the company’s stock valued at $4,375,000 after purchasing an additional 27,900 shares during the period. Gofen & Glossberg LLC IL increased its holdings in shares of Johnson & Johnson by 1.0% in the fourth quarter. Gofen & Glossberg LLC IL now owns 564,586 shares of the company’s stock valued at $72,860,000 after purchasing an additional 5,735 shares during the period. Finally, First United Bank Trust increased its holdings in shares of Johnson & Johnson by 0.7% in the fourth quarter. First United Bank Trust now owns 20,481 shares of the company’s stock valued at $2,643,000 after purchasing an additional 150 shares during the period. 67.35% of the stock is currently owned by institutional investors.
In other news, Director Marillyn A. Hewson purchased 3,000 shares of the stock in a transaction dated Tuesday, June 11th. The stock was acquired at an average cost of $139.68 per share, for a total transaction of $419,040.00. Following the completion of the transaction, the director now directly owns 3,000 shares in the company, valued at approximately $419,040. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 0.23% of the company’s stock.
A number of brokerages have recently weighed in on JNJ. Bank of America reissued a “hold” rating and issued a $150.00 price objective on shares of Johnson & Johnson in a report on Tuesday, July 16th. Credit Suisse Group set a $156.00 price target on Johnson & Johnson and gave the stock a “buy” rating in a research report on Thursday, July 18th. Goldman Sachs Group assumed coverage on Johnson & Johnson in a research report on Tuesday, May 28th. They set a “buy” rating on the stock. Royal Bank of Canada reissued a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, July 16th. Finally, Barclays assumed coverage on Johnson & Johnson in a report on Friday, June 21st. They set a “hold” rating and a $140.00 target price for the company. Five equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $148.56.
NYSE:JNJ opened at $130.54 on Friday. The stock has a 50 day moving average price of $134.10 and a 200 day moving average price of $136.70. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.04 and a current ratio of 1.33. The stock has a market cap of $352.12 billion, a PE ratio of 15.96, a P/E/G ratio of 2.26 and a beta of 0.69. Johnson & Johnson has a one year low of $121.00 and a one year high of $148.99.
Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, July 16th. The company reported $2.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.42 by $0.16. The company had revenue of $20.56 billion during the quarter, compared to analysts’ expectations of $20.39 billion. Johnson & Johnson had a return on equity of 38.63% and a net margin of 20.08%. The firm’s quarterly revenue was down 1.3% compared to the same quarter last year. During the same quarter last year, the firm earned $2.10 earnings per share. As a group, analysts predict that Johnson & Johnson will post 8.6 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th will be paid a dividend of $0.95 per share. The ex-dividend date is Monday, August 26th. This represents a $3.80 annualized dividend and a yield of 2.91%. Johnson & Johnson’s dividend payout ratio (DPR) is 46.45%.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Featured Article: Green Investing
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.